Elsevier Launches International Journal for Parasitology: Drugs and Drug Resistance

AMSTERDAM, June 22, 2011 -

New Open Access Journal Dedicated to
Collaborations and Cutting-Edge Research in
Parasitology

Elsevier, a world-leading provider of scientific, technical and
medical information products and solutions, in association with the
Australian Society for
Parasitology, is pleased to announce the launch of a new
journal, International Journal for Parasitology: Drugs and Drug
Resistance. The new electronic open access journal is closely
affiliated with the leading parasitology journal, International
Journal for Parasitology, and will address a critical area of
research, covering anti-parasite drug identification, development
and evaluation, and parasite drug resistance. The journal’s remit
also includes research into natural products as anti-parasitic
agents, and bioactive parasite products.

Prof Terry Spithill, President of the Australian Society for
Parasitology, said, “The Society is delighted to have fostered the
founding of this new Journal which we anticipate will provide a
stellar forum for the dissemination of original discoveries in the
pharmacological control of parasites of human and veterinary
significance.”

Original research includes the development of novel and
innovative concepts and ideas, as well as experimental and
observational science that raises new hypotheses. The Journal
encourages critical comment and debate on matters of current
controversy in the area of parasite drug resistance and
anti-parasite drugs via “Current Opinions”. Studies can be aimed at
unicellular or multicellular parasites of human or veterinary
importance.

“We are delighted to continue our excellent relationship with
the Australian Society for Parasitology, and are confident that
IJP:DDR will quickly establish itself as the leading journal in its
field,” added Dale Seaton, Executive Publisher for Elsevier. “In
addition, by utilizing the open access model option for this title,
Elsevieris enabling the broadest possible access to quality
research content in a sustainable way that meets the society’s
needs.”

More information about the scope of articles accepted for
submission are available on the href="www.elsevier.com/wps/find/journaldescription.cws_home/726218/description#description">
Journal’s website. Article submissions for IJP:DDR can be made
at href="ees.elsevier.com/ijpddr/">ees.elsevier.com/ijpddr/

About Elsevier

Elsevier is a world-leading provider of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to
publish more than 2,000 journals, including The Lancet ( href="www.thelancet.com">www.thelancet.com) and
Cell ( href="www.cell.com">www.cell.com), and close to
20,000 book titles, including major reference works from Mosby and
Saunders. Elsevier’s online solutions include SciVerse
ScienceDirect ( href="www.sciencedirect.com">www.sciencedirect.com),
SciVerse Scopus ( href="www.scopus.com">www.scopus.com), Reaxys ( href="www.reaxys.com">www.reaxys.com), MD Consult
(www.mdconsult.com)
and Nursing Consult ( href="www.nursingconsult.com">www.nursingconsult.com),
which enhance the productivity of science and health professionals,
and the SciVal suite ( href="www.scival.com">www.scival.com) and MEDai’s
Pinpoint Review ( href="www.medai.com">www.medai.com), which help
research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( href="www.elsevier.com">www.elsevier.com) employs
7,000 people worldwide. The company is part of Reed Elsevier Group
PLC ( href="www.reedelsevier.com">www.reedelsevier.com),
a world-leading publisher and information provider, which is
jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange),
RUK and ENL (New York Stock Exchange).

Media contact
Harald Boersma
Senior Manager, Corporate Relations, Elsevier
href="mailto:H.boersma@elsevier.com">H.boersma@elsevier.com

+31-20-485-27-36

.